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Abstract: Background: Pneumonias are the most frequent infectious diseases, characterized by a 
high prevalence especially among children and adults at risk. The socio-economic impact caused 
by Streptococcus pneumoniae is evaluated in terms of morbidity, death rate and hospitalizations. 
Objective: The aim of the study was to demonstrate the potential economic advantages by 
implementation of an active anti-pneumococcal 13-valent vaccine strategy in Campania region 
(Southern Italy) in two different categories of subjects, children (aged 0-12), and adults (aged 50-
79) at risk (hypertension, nephropathies, COPD and heart diseases) 
Methods: Vaccination costs were compared with costs necessary to treat avoidable diseases in the 
presence and absence of a vaccination program.  
Results: Offering anti-pneumococcal 13-valent vaccine to the paediatric population was quanti-
fied as saving one million euros for Italian national health service in two years. In addition, offer-
ing anti-pneumococcal vaccine to adults at risk would generate a return of around 29 million eu-
ros.  
Conclusion: In both cases, offering anti-pneumococcal 13-valent vaccine was proven to be a help-
ful political health strategy, not only in consideration of a reduction of cases but also in view of 
the favourable economic impacts.	  
Keywords: Pneumococcal disease, 13-valent vaccine, budget impact analysis, Streptococcus pneumoniae, bacterium, etiologic 
agent. 
1. INTRODUCTION  
Streptococcus pneumoniae is a Gram-positive bacterium 
widely common in the general population. It is able to colo-
nize the mucosa of the upper airways and it could cause in-
fections, even serious, such as sinusitis, otitis, pneumonia 
and meningitis [1, 2]. In the last decades, to fight the signifi-
cant increase of the infections, several vaccine formulas have 
already been available, capable of assuring high levels of 
protection in both paediatric population (around 90%) and in 
adult subjects at risk of, or affected by specific diseases [3-
6].  
Anti-pneumococcal vaccination shows a good perform-
ance in at least 80% of healthy adults, with a rate of effi-
ciency slightly lower for elderly people, but acceptable in 
subjects affected by chronic diseases [7, 8]. Furthermore, an 
excellent safety profile has been demonstrated, also when it  
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is administrated in conjunction with other vaccines [9, 10]. A 
wide availability of anti-pneumococcal vaccines would not 
only reduce cases of infection/disease, but would also protect 
the remaining population due to the reduced circulation of 
the etiologic agent [11-13]. The socio-economic impact of 
diseases caused by Streptococcus pneumoniae is evaluated in 
terms of excess of morbidity, mortality and hospitalizations 
[14-18]. World Health Organization (WHO) estimates that 
there are at least 1.6 million deaths annually caused by S. 
pneumoniae, with 1 million of these among children below 5 
years [19]. 
Pneumonias are the most frequent infectious disease, 
characterized by a high prevalence especially among chil-
dren, adults at risk and elderly people, with clinical hetero-
geneity and variable severity [20]. Several studies estimated 
that incidence varies among countries, but, as reported in 
recent years, it is clear that the number of cases and mortality 
increase significantly due to pneumonia with age.  
Pneumonia represents the most frequent cause of death 
from pneumococcal infection and this has a considerable 
impact on health systems all over the world [21, 22]. In the 
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absence of adequate vaccination strategies, it will determine 
an inevitable negative impact on related health system costs 
in the near future [20-24].  
Prevenar 13® is currently the most utilized conjugated 
anti-pneumococcal vaccine in our country, considering the 
high immunogenicity and safety demonstrated over the years 
[16]. Considering the remarkable epidemiological, clinical 
and economic relevance of pneumococcal diseases in differ-
ent ages, especially in paediatric and adults-at-risk subjects, 
European Medical Agency (EMA) approved and extended 
the use of Prevenar 13® for individuals of all ages between 
April 2010 and June 2013. In fact, today PVC13 is com-
monly referred to as the anti-pneumococcal vaccine “for 
life”. http://www.ema.europa.eu 
Despite the most recent national vaccine plans, we under-
line the clinical efficiency of anti-pneumococcal vaccine in 
the prevention of infections due to Streptococcus pneumo-
niae in subjects of all ages. Up to now, there is a condition of 
‘absence of right’, so offering such a vaccine is not included 
or covered by any national regulations [25, 26]. On the other 
hand, this situation could be an opportunity to reorganize the 
entire system of vaccination policies in the various local 
health units around the country, in an attempt to improve the 
efficiency of the offering [27].  
This study supports the hypothesis that an active offering 
of an anti-pneumococcal vaccine is an important health-
related political choice supported not only by clinical effi-
ciency data, but also by results regarding economic return, 
with reference to results obtained during several studies con-
ducted in Campania region [28, 29]. 
2. MATERIALS AND METHODS  
Budget impact analysis (BIA) was applied in two differ-
ent work hypotheses.  
2.1. First Hypothesis  
We estimated, through a budget impact analysis (BIA), 
time required for an economic return for the National Health 
System derived from an active offering of the conjugated 
vaccine 13-valent to newborns in Campania region in 2009 
(about two years). 
First of all, we estimated the incidence of the 3 principal 
pneumococcal diseases expected in the paediatric population 
(otitis, pneumonia and meningitis) in the presence and ab-
sence of a vaccination program. Data was deduced from the 
studies results by Esposito S, La Torre G and Pavia M [30-
32]. Then we estimated the cost of treating every single case 
of otitis, pneumonia and pneumococcal meningitis, with ref-
erence to studies conducted on these issues by Lucioni [33], 
Giorgi-Rossi [34], Colombo [35] and Berto [36]. This cost 
was multiplied for the number of estimated events in the two 
hypothesised scenarios. Subsequently, we calculated the cost 
of vaccination (local health unit’s price of medicine + hourly 
cost of operator) and the expense for the entire immunization 
program (Table 1). 
The potential economic advantages of the active offering 
of Prevenar 13® to all newborns in the region were estimated 
for each year considering the difference between the costs to 
be sustained for the number of cases of avoidable pneumo-
coccal diseases in vaccinated subjects and those in the non 
vaccinated subjects.  
2.2. Second Hypothesis  
We estimated savings obtainable by an active offering of 
an anti-pneumococcal vaccine to the population aged 50-79 
at risk of diabetes, hypertension, nephropathies, COPD and 
heart conditions (about 1 million of individuals in the region) 
due to a budget impact analysis (BIA). 
The impact of PCV vaccination programs was compared 
with a no-vaccination scenario. The analyses were performed 
on the resident population in Campania on January 1 2009, 
as reported by the National Institute for Statistics 
(IstitutoNazionale di Statistica, ISTAT), without considering 
sex and origin [37]. Considering the average national cover-
age for the last influenza immunization program in Italy in 
elderly people, vaccination coverage of the targeted cohorts 
was supposed to be 60% [38]. 
Table 1. Costs in Euros of anti-pneumococcal and S.pneumoniae pathologies vaccination. 
Costs  Amount (€) Source 
Vaccine  42,58 Price for AASSLL 
Vaccine operator 4,12 ISTAT 
Vaccination  140* Estimated elaboration* 
Otitis: 
- Paediatric visit 
- Clavulanic acid + amoxicillin  
30,59 
18,54 
12,05 
Lucioni, 1999 
Retail price 
Pneumonia: 
- Paediatric visit  
- Recovery  
1.868,54 
18,54 
1.850 
Istat 
DRG Campania 
Meningitis 10.696 Lucioni, 1999 
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Community-Acquired Pneumonia (CAP) incidence was 
considered about 3.34% [39]. The clinical outcome of the 
analysis was hospitalized pneumococcal CAP cases in adult 
population (50-79 y). Data were obtained from the hospital 
discharge forms (Scheda di Dimissione Ospedaliera, SDO) 
of respiratory departments which participate in the training 
regional network [40]. During the years 2010-2011, 18.965 
CAP cases were reported in these SDOs. 
Considering that the overall rate of CAP due to S. pneu-
moniae is about 40%, the number of pneumococcal CAP per 
year among reported cases was estimated to be 3.793 [41]. 
Considering previous studies, the vaccine efficacy 
against pneumococcal pneumonia was assumed to be 87.5%, 
so this value was used to calculate the number of avoided 
cases for each vaccination strategy [38, 42-44]. 
Expected cases were corrected for the global mortality 
rate, as obtained from 2010 ISTAT data [45]. 
The economic model was based on the difference be-
tween the costs sustained with (vaccine plus treatment for 
expected cases) and without (only expected cases) a vaccina-
tion program. 
The cost of the vaccine was 42.5 Euro per dose; the cost 
of a CAP case due to S. pneumoniae was assumed to be the 
average of costs for complicated and non-complicated 
pneumonia cases, equal to €3.809 [46]. Costs were updated 
to a rate of 3%.  
3. RESULTS 
3.1. First Hypothesis  
In such a case, the number of cases (%) of diseases 
caused by S. pneumoniae, in the presence and absence of 
vaccination programs (Table 2) is estimated. After that, three 
possible scenarios were hypothesized: 
In the first case, supposing that the entire regional popu-
lation in the year 2009 would be vaccinated, the cost of the 
vaccination program would be € 8,363,410.00. Conversely, 
at the end of the two-year period under consideration, ob-
tainable clinical benefits (fewer cases of otitis, meningitis 
and pneumonia) would provide the opportunity to overthrow 
the costs due to these diseases, with a quantifiable economic 
advantage of about 1 million euros (Table 3).  
In the second case, coverage for 80% of newborns was 
considered, with a consequential potential return in eco-
nomic terms of € 804,635 at the end of two years. This latter 
hypothesis considered the vaccination of half the paediatric 
population in the year 2009: also, in this case, a quantifiable 
advantage of € 502,897 would be achieved after only two 
years (Table 4).  
3.2. Second Hypothesis  
Because of the processing of epidemiological data, we 
estimated the number of expected pneumonias in the pres-
ence and absence of a vaccination program in subjects at risk 
aged 50-79 during the period under consideration. Particu-
Table 2. Number of cases (%) of Spn pathologies estimated in case of presence and absence of vaccination programs. 
With Vaccination Program Without Vaccination Program 
 
Number of cases (%) Number of cases (%) 
Otitis 23.878 (40%) 29.848 (50%) 
Pneumonia 896 (1,5%) 2.985 (5%) 
Meningitis 3 (0,05%) 59 (0,1%) 
Total 24.777 32.892 
Table 3. Costs in Euros for pneumococcal pathologies with presence or absence of a vaccination program and advantage attain-
able through active offer to paediatric population. 
COSTS (€) 
FIRST YEAR SECOND YEAR 
With vaccination  Without vaccination  With vaccination  Without vaccination  
Costs at the end of 
the two years VACCINATION 
8.363.410 - - - 8.363.410 
Otitis 730.428,02 913.050,32 730.428,02 913.050,32 365.244,6 
Pneumonia 1.674.211,84 5.577.218,192 1.674.211,84 5.577.218,192 7.806.012,70 
D
is
ea
se
 
Meningitis 32.089,77 631.064,00 32.089,77 631.064,00 1.197.948,46 
Obtainable economic 
benefit 
- - - - 1.005,796 
*59.696 children 
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larly, expected pneumonias in the first case would be around 
509, compared to 4,083 estimated in the second case, with a 
reduction of 3,574 cases. Subsequently, the design of the 
study allowed quantification in economic terms of the vacci-
nation program and costs for expected diseases in the two 
prospected scenarios. In the first approximation, we found 
that in the first year, the cost that must be sustained to vacci-
nate all adults at risk aged 50-79 (60% of them) was € 
25,321,482, which is about twice the cost needed to treat 
expected cases of pneumonia in the absence of a vaccination 
program. Thanks to the vaccination strategy, after some ob-
vious, expected, costs during the first year, we found a sav-
ing at the end of the second year due to the reduction of 
cases of pneumonia (Table 5). 
4. DISCUSSION 
Diseases due to Streptococcus pneumoniae are a relevant 
and current health issue that represents one of the most rele-
vant causes of morbidity and mortality in Italy [1, 2].  
Only by appropriate preventive measures - specific vac-
cination strategies - the quality of life of patients can be im-
proved and the number of cases can be reduced. 
A prevention approach is fundamental: it moves from 
“expectation medicine” to “initiative medicine”. It is very 
important to create a multidisciplinary network. 
National vaccine plans exist as guidelines or opportuni-
ties to plan strategies on behalf of Public Healthcare organi-
zations to promote health [25, 26].  
It must also be stressed that today there is much differ-
ence between mandatory and optional vaccinations. 
The latest National Vaccine Plan promotes the anti-
pneumococcal vaccination strategy for all individuals in the 
nation. 
In past years, the aspect of the cost-effectiveness of vac-
cinations has been addressed with "ad hoc" analysis. A strat-
egy is considered efficient only if it is also effective, accord-
ing to recognized high-level scientific evidence. 
CONCLUSION  
This study demonstrates how a vaccination strategy can 
generate economic savings [28, 29].  
The analysis has two important limits: 1) it does not con-
sider indirect costs; 2) it considers only 5 years. This strategy 
could represent a sustainable and savings-producer health 
policy. 
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